WEBULL
WebtradeDownload

BioDlink International (SEHK:1875) Stock Rebound Meets Shrinking Revenue And Fresh Losses

Simply Wall St · 2d ago

BioDlink International has been trading like a recovery story, with the stock up about 17% over the past month. However, H1 2026 results underline that this is still a loss making biotech with a valuation built on hope rather than profit. The headline this half is the profit squeeze. Revenue came in at ¥246.011 million, while net income excluding extra items showed a loss of ¥58.517 million and basic earnings per share were also in the red. The share price reaction now rests on how long investors are willing to fund the gap between sales and sustainable earnings.

Love the recent share price rebound in BioDlink International but concerned about the ongoing losses and profit squeeze? Take a look at our 295 resilient stocks with low risk scores for companies that pair revenue with stronger earnings visibility and lower risk profiles.

H1 2026 Earnings Summary

  • Revenue H1 2026 vs. H1 2025: ¥246.011 million vs. ¥489.140 million (revenue decline)
  • Net Income H1 2026 vs. H1 2025: loss of ¥58.517 million vs. profit of ¥4.062 million (swing back into loss)
  • Basic EPS H1 2026 vs. H1 2025: loss of ¥0.08 per share vs. earnings of ¥0.005601 per share (earnings moved into loss)
  • Trailing 12 Month Net Income to H1 2026 vs. TTM to H1 2025: loss of ¥162.948 million vs. profit of ¥7.26 million (shift to full year loss on a trailing basis)

Prefer clean charts over long lists of financial figures and earnings tables? View BioDlink International's full financial picture with a clear visual overview of its recent revenue and earnings trends in the company report for BioDlink International.

SEHK:1875 Trailing 12-Month Earnings & Revenue History as at Aug 2026
SEHK:1875 Trailing 12-Month Earnings & Revenue History as at Aug 2026

BioDlink bullish hopes versus shrinking revenue base

For anyone leaning bullish on BioDlink International as a platform oncology and services story, the latest figures make that view harder to support in the near term. Revenue in H1 2026 is roughly half of H1 2025 and the company moved from profit to loss on both the half year and trailing 12 month views. The share price has rebounded about 17% over 30 days, yet the earnings trend does not currently support a clear recovery story grounded in rising sales or improving profitability.

Profit squeeze keeps the BioDlink bear case alive

The bearish side of the BioDlink International debate finds more support in these results. Revenue has contracted sharply while trailing 12 month net income shifted from a small profit to a sizeable loss of ¥162.948 million. H1 2026 also shows a fresh loss with basic EPS back in negative territory. Recent share price gains of about 8% over 7 days do not erase the 10% decline over 90 days, which indicates that investors are still treating this as a loss making biotech rather than a proven cash generator.

With BioDlink International still unprofitable and traditional earnings-based valuation limited, the key consideration is whether the balance sheet can support this story. Review the solvency, cash runway and debt load in the financial health analysis of BioDlink International stock.

Stay Ahead Of Your Next Move

BioDlink International is still working through losses and a profit squeeze, so it makes sense to track it closely rather than react to every price move. Register for free with Simply Wall St and add BioDlink International to your Watchlist to monitor the share price against fair value and wait for an entry point that fits your plan. Once invested, keep your decisions focused with the Portfolio Command Center that cuts through noise and highlights only the key changes that matter to your holdings. Round out your research by tapping into crowd views and debate in the Community so you can spot potential catalysts or risks early and stay ahead of the market.

Seeking Curiosity Driven Stock Alternatives

Fresh ideas can move before the headlines catch up. Spot breakouts, capture momentum while it matters, and set aside stories that are slipping under the radar for now. Get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.